Feliza Mirasol

Despite the disappointing therapeutic performance of ADCs thus far, the pipeline still boasts promising prospects.

Process analytical testing for biopharmaceuticals requires enhanced methods due to complex bioprocesses.

The development of emerging therapies poses unique manufacturing and formulation challenges for drug developers as candidates like cell and gene therapies advance through the pipeline.